{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:59:58Z","timestamp":1794067198892,"version":"4.8.0"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Glycopeptide antibiotics such as vancomycin are frequently utilized to treat resistant Gram-positive infections such as methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>. The current literature on glycopeptide and lipoglycopeptide structure, hypersensitivity and potential cross-reactivity was reviewed, highlighting implications for safe prescribing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Structurally similar, glycopeptides could theoretically cross-react. Immediate reactions to vancomycin include non-IgE-mediated reactions (e.g. red man syndrome) and IgE-mediated hypersensitivity (e.g. anaphylaxis), sharing clinical features. Vancomycin can activate mast cells via MAS-related G-protein-coupled receptor X2, an IgE-independent receptor implicated in non-IgE reactions. In-vivo and in-vitro testing for suspected IgE-mediated reactions to glycopeptides remain ill-defined. Vancomycin is increasingly recognized to cause severe cutaneous adverse reactions (SCAR), with drug reaction with eosinophilia and systemic symptoms (DRESS) predominantly reported. Vancomycin DRESS has been associated with HLA-A<jats:sup>\u2217<\/jats:sup>32:-01, with a number needed to prevent of 1 in 74. Data demonstrating cross-reactivity amongst glycopeptides and lipoglycopeptides is limited to case reports\/series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Further studies and in-vivo<jats:italic toggle=\"yes\">\/<\/jats:italic>in-vitro diagnostics are required for better differentiation between IgE and non-IgE glycopeptide reactions. Despite its association with vanomycin DRESS, utility of pharmacogenomic screening for HLA-A<jats:sup>\u2217<\/jats:sup>32: 01 is ill-defined. Although HLA-A<jats:sup>\u2217<\/jats:sup>32:01 has been associated with vancomycin DRESS, its utility for pharmacogenomic screening is ill defined. Further clinical and immunological cross-reactivity data for glycopeptide\/lipoglycopeptide antibiotics is required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000000665","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T09:47:49Z","timestamp":1592905669000},"page":"352-361","source":"Crossref","is-referenced-by-count":25,"title":["Adverse reactions to vancomycin and cross-reactivity with other antibiotics"],"prefix":"10.1097","volume":"20","author":[{"given":"Joseph F.","family":"De Luca","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Allergy, The Royal Melbourne Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha E.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Centre for Antibiotic Allergy and Research, Austin Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Centre for Antibiotic Allergy and Research, Austin Health"},{"name":"Department of Medicine (Austin Health), University of Melbourne, Heidelberg"},{"name":"The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"(Suppl. D)","key":"R1-20230827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/14.suppl_D.1","article-title":"Vancomycin use: an historical review","volume":"14","author":"Griffith","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"R2-20230827","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinte.1962.03620170005002","article-title":"Vancomycin in serious staphylococcal infections","volume":"109","author":"Geraci","year":"1962","journal-title":"Arch Intern Med"},{"key":"R3-20230827","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0924-8579(98)00025-9","article-title":"Comparative safety of teicoplanin and vancomycin","volume":"10","author":"Wilson","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"R4-20230827","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/cc1871","article-title":"Red man syndrome","volume":"7","author":"Sivagnanam","year":"2003","journal-title":"Critical Care"},{"key":"R5-20230827","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.anai.2016.03.030","article-title":"Immune-mediated reactions to vancomycin: a systematic case review and analysis","volume":"116","author":"Minhas","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R6-20230827","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(18)32218-9","article-title":"Antibiotic allergy","volume":"393","author":"Blumenthal","year":"2019","journal-title":"Lancet"},{"issue":"(Suppl 1)","key":"R7-20230827","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R8-20230827","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/BF01715507","article-title":"Teicoplanin: 10 years of clinical experience","volume":"22","author":"Trautmann","year":"1994","journal-title":"Infection"},{"key":"R9-20230827","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00253-009-2107-4","article-title":"Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives","volume":"84","author":"Jung","year":"2009","journal-title":"Appl Microbiol Biotechnol"},{"key":"R10-20230827","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"(Suppl. 5)","key":"R11-20230827","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1120009X.2000.11782313","article-title":"Comparative pharmacokinetics of teicoplanin and vancomycin","volume":"12","author":"Harding","year":"2000","journal-title":"J Chemother"},{"key":"R12-20230827","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"R13-20230827","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20230827","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"R15-20230827","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/AAC.22.3.391","article-title":"Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations","volume":"22","author":"Rotschafer","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20230827","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20230827","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1128\/AAC.35.12.2551","article-title":"Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses","volume":"35","author":"Del Favero","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20230827","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R19-20230827","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14787210.3.3.325","article-title":"Oritavancin: a new avenue for resistant Gram-positive bacteria","volume":"3","author":"Mercier","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"(Suppl 2)","key":"R20-20230827","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R21-20230827","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20230827","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4167\/jbv.2015.45.2.67","article-title":"Glycopeptide antibiotics: structure and mechanisms of action","volume":"45","author":"Kang","year":"2015","journal-title":"J Bacteriol Virol"},{"key":"R23-20230827","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u2018lineless antibiotics\u2019 for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R24-20230827","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"R25-20230827","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R26-20230827","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20230827","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2017.01.034","article-title":"Outpatient treatment of osteomyelitis with telavancin","volume":"50","author":"Schroeder","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R28-20230827","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s15010-012-0328-4","article-title":"Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection","volume":"41","author":"Boss\u00e9","year":"2013","journal-title":"Infection"},{"key":"R29-20230827","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12691\/ajmcr-7-1-5","article-title":"Red man syndrome with oral vancomycin: a case report","volume":"7","author":"Arroyo-Mercado","year":"2019","journal-title":"Am J Med Case Rep"},{"key":"R30-20230827","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1757-1626-1-111","article-title":"An elderly woman with \u2018Red Man Syndrome\u2019 in association with oral vancomycin therapy: a case report","volume":"1","author":"Bailey","year":"2008","journal-title":"Cases J"},{"key":"R31-20230827","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/106002809402800505","article-title":"Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function","volume":"28","author":"Bergeron","year":"1994","journal-title":"Ann Pharmacother"},{"key":"R32-20230827","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/157.3.502","article-title":"Vancomycin and the red-man syndrome: pharmacodynamics of histamine release","volume":"157","author":"Polk","year":"1988","journal-title":"J Infect Dis"},{"key":"R33-20230827","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fped.2014.00055","article-title":"Red man syndrome following intraperitoneal vancomycin in a child with peritonitis","volume":"2","author":"Domis","year":"2014","journal-title":"Front Pediatr"},{"key":"R34-20230827","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jocn.2018.01.044","article-title":"Red man syndrome caused by vancomycin powder","volume":"50","author":"Nagahama","year":"2018","journal-title":"J Clin Neurosci"},{"key":"R35-20230827","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/infdis\/160.5.876","article-title":"Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome","volume":"160","author":"Sahai","year":"1989","journal-title":"J Infect Dis"},{"key":"R36-20230827","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/AAC.34.5.765","article-title":"Comparison of vancomycin- and teicoplanin-induced histamine release and \u2018red man syndrome\u2019","volume":"34","author":"Sahai","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-20230827","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/pgmj.75.879.41","article-title":"Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin","volume":"75","author":"Khurana","year":"1999","journal-title":"Postgrad Med J"},{"key":"R38-20230827","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/BF01976748","article-title":"Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells","volume":"40","author":"Horinouchi","year":"1993","journal-title":"Agents Actions"},{"key":"R39-20230827","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF01980877","article-title":"Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1)","volume":"32","author":"Williams","year":"1991","journal-title":"Agents Actions"},{"key":"R40-20230827","first-page":"e5","article-title":"Brief communication: MRGPRX2, atopic dermatitis and red man syndrome","volume":"2","author":"Azimi","year":"2017","journal-title":"Itch (Phila)"},{"key":"R41-20230827","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"R42-20230827","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navin\u00e9s-Ferrer","year":"2018","journal-title":"Sci Rep"},{"key":"R43-20230827","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"key":"R44-20230827","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.anai.2016.03.030","article-title":"Immune-mediated reactions to vancomycin","volume":"116","author":"Minhas","year":"2016","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"R45-20230827","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2018.04.014","article-title":"Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6)","volume":"121","author":"Harper","year":"2018","journal-title":"Br J Anaesth"},{"key":"R46-20230827","first-page":"229","article-title":"Antimicrobial anaphylaxis: the changing face of severe antimicrobial allergy","volume":"75","author":"Hall","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R47-20230827","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.37.10.2139","article-title":"Vancomycin skin tests and prediction of \u2018red man syndrome\u2019 in healthy volunteers","volume":"37","author":"Polk","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-20230827","first-page":"984","article-title":"A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis","volume":"3","author":"Otani","year":"2015","journal-title":"J Allergy Clin Immunol: Pract"},{"key":"R49-20230827","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10875-019-00707-3","article-title":"Serum tryptase cannot differentiate vancomycin-induced anaphylaxis from red man syndrome","volume":"39","author":"Noguchi","year":"2019","journal-title":"J Clin Immunol"},{"key":"R50-20230827","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00000542-199809000-00010","article-title":"Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions","volume":"89","author":"Renz","year":"1998","journal-title":"Anesthesiology"},{"key":"R51-20230827","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000542-200004000-00026","article-title":"Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells","volume":"92","author":"Veien","year":"2000","journal-title":"Anesthesiology"},{"key":"R52-20230827","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1081-1206(10)62416-7","article-title":"Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels","volume":"84","author":"Chopra","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R53-20230827","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1345\/aph.1A002","article-title":"Desensitization protocols for vancomycin hypersensitivity","volume":"35","author":"Wazny","year":"2001","journal-title":"Ann Pharmacother"},{"key":"R54-20230827","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaip.2016.04.026","article-title":"A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions","volume":"4","author":"Trubiano","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R55-20230827","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.jac.a020861","article-title":"Risk factors for adverse cutaneous reactions associated with intravenous vancomycin","volume":"39","author":"Korman","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R56-20230827","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R57-20230827","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2019.02.002","article-title":"Vancomycin-associated drug-induced hypersensitivity syndrome","volume":"81","author":"Madigan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R58-20230827","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/imj.12660","article-title":"Vancomycin vintage: my favourite DRESS","volume":"45","author":"Korman","year":"2015","journal-title":"Intern Med J"},{"key":"R61-20230827","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"key":"R62-20230827","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QCO.0000000000000323","article-title":"Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity","volume":"29","author":"Konvinse","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"R63-20230827","first-page":"e5015","article-title":"A fatal case of vancomycin associated drug reaction with eosinophilia and systemic symptoms syndrome in a septuagenarian","volume":"11","author":"Gangireddy","year":"2019","journal-title":"Cureus"},{"key":"R64-20230827","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/cid\/ciu126","article-title":"Severe cutaneous adverse reactions related to systemic antibiotics","volume":"58","author":"Lin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R65-20230827","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R66-20230827","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijantimicag.2006.11.022","article-title":"Teicoplanin hypersensitivity syndrome","volume":"29","author":"Lye","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R67-20230827","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.medmal.2018.01.002","article-title":"Teicoplanin-induced DRESS syndrome: the importance of skin tests","volume":"48","author":"Ben Romdhane","year":"2018","journal-title":"Med Mal Infect"},{"key":"R68-20230827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40800-016-0042-8","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) with teicoplanin: a case report","volume":"4","author":"Ebrahimpour","year":"2017","journal-title":"Drug Saf Case Rep"},{"key":"R69-20230827","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40560-015-0114-3","article-title":"Vancomycin-induced acute generalized exanthematous pustulosis (AGEP) masquerading septic shock-an unusual presentation of a rare disease","volume":"3","author":"Mawri","year":"2015","journal-title":"J Intensive Care"},{"key":"R70-20230827","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.amjmed.2004.01.007","article-title":"Acute generalised exanthematous pustulosis mimicking septic shock","volume":"116","author":"Lesterhuis","year":"2004","journal-title":"Am J Med"},{"key":"R71-20230827","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4037\/ajcc2013987","article-title":"Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome","volume":"22","author":"Mohyuddin","year":"2013","journal-title":"Am J Crit Care"},{"key":"R72-20230827","first-page":"225","article-title":"A pentad of vancomycin reactions","volume":"9","author":"O\u2019Brien","year":"2011","journal-title":"Skinmed"},{"key":"R73-20230827","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bcp.13827","article-title":"Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases","volume":"85","author":"Garel","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R74-20230827","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaip.2016.09.043","article-title":"Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis","volume":"5","author":"Trubiano","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R75-20230827","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jac\/dkr448","article-title":"Detection of vancomycin levels in patients receiving telavancin but not vancomycin","volume":"67","author":"Gelfand","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R76-20230827","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1128\/AAC.03785-14","article-title":"Variability in telavancin cross-reactivity among vancomycin immunoassays","volume":"58","author":"McConeghy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R77-20230827","first-page":"1230","article-title":"Graded dalbavancin challenge in a patient with severe vancomycin hypersensitivity reaction","volume":"70","author":"Ishizuka","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R78-20230827","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3904\/kjim.2018.404","article-title":"Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors","volume":"35","author":"Kim","year":"2019","journal-title":"Korean J Intern Med"},{"key":"R79-20230827","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.jcf.2018.08.003","article-title":"Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: a case series","volume":"17","author":"Bernstein","year":"2018","journal-title":"J Cyst Fibros"},{"key":"R80-20230827","doi-asserted-by":"crossref","first-page":"625","DOI":"10.12659\/AJCR.899149","article-title":"DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration: a case report","volume":"17","author":"Miyazu","year":"2016","journal-title":"Am J Case Rep"},{"key":"R81-20230827","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/jcpt.12159","article-title":"Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin","volume":"39","author":"Yang","year":"2014","journal-title":"J Clin Pharmacy Therap"},{"key":"R82-20230827","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2710.2011.01291.x","article-title":"High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy","volume":"37","author":"Hsiao","year":"2012","journal-title":"J Clin Pharmacy Therap"},{"key":"R83-20230827","first-page":"71","article-title":"Reaction to teicoplanin with tolerance to vancomycin","volume":"18","author":"Macias","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R84-20230827","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1345\/aph.1H633","article-title":"Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin","volume":"41","author":"Hsiao","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R85-20230827","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3346\/jkms.2006.21.6.1108","article-title":"A case of hypersensitivity syndrome to both vancomycin and teicoplanin","volume":"21","author":"Kwon","year":"2006","journal-title":"J Korean Med Sci"},{"key":"R86-20230827","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00006454-199402000-00026","article-title":"A four-year-old child with teicoplanin allergy but no evidence of cross-reaction with vancomycin","volume":"13","author":"de Vries","year":"1994","journal-title":"Pediatr Infect Disease J"},{"key":"R87-20230827","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0163-4453(98)91077-5","article-title":"Glycopeptide-induced vasculitis: cross-reactivity between vancomycin and teicoplanin","volume":"37","author":"Marshall","year":"1998","journal-title":"J Infect"},{"key":"R88-20230827","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(86)91933-1","article-title":"Allergic cross-reactivity of teicoplanin and vancomycin","volume":"1","author":"McElrath","year":"1986","journal-title":"Lancet"},{"key":"R89-20230827","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jac\/28.3.476","article-title":"Allergic cross-reaction of teicoplanin and vancomycin","volume":"28","author":"Grek","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R90-20230827","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.coph.2004.04.006","article-title":"Glycopeptides in clinical development: pharmacological profile and clinical perspectives","volume":"4","author":"Van Bambeke","year":"2004","journal-title":"Curr Opin Pharmacol"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T03:33:40Z","timestamp":1693107220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000665","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}